Funding for this research was provided by:
Received: 14 May 2022
Accepted: 31 July 2022
First Online: 16 August 2022
: This study was performed in accordance with the declaration of Helsinki.
: Not Applicable.
: RSS, BZR, TJN, DBB, KM, CFM, MGV, BLS, and DTR are employed by Oncocyte Corporation, the commercial entity that markets the 27-gene IO Score as DetermaIO<sup>™</sup>. MEH serves on advisory boards for Bristol Myers Squibb, Nektar Therapeutics, Janssen Pharmaceuticals, Exelixis, and CRISPR Therapeutics and receives research funding from Achilles, Apexigen, Astellas, AstraZeneca, Bayer, Bristol Myer Squibb, Clovis, Corvus, Eli Lilly, Endocyte, Genentech, Genmab, GSK, Innocrin, Iovance, KSQ Therapeutics, MedImmune, Merck, Nektar Therapeutics, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, SQZ Biotech, Seattle Genetics. His spouse is employed by Arvinas.